Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENGUIN: JNJ-3989 + PegIFN-alpha2a in Chronic Hepatitis B
NCT04667104Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of tomligisiran in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Started Feb 2021; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04667104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667104.